Clinical trials: Emphysema
Neurodegenerative Diseases, Osteoarthritis
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF).
- Conditions
- Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases
- Trial name
- NCT01953523
- Testing
- Administration of autologous adipose derived SVF
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Elliot Lander
Asthma, Bronchitis
Tucson Epidemiology Study of Chronic Obstructive Lung Diseases
To determine the natural history, etiology, and interrelationships of emphysema, chronic bronchitis, asthma, and related airways obstructive diseases.
- Conditions
- Asthma, Bronchitis, Emphysema, Lung Diseases, Obstructive
- Trial name
- NCT00005279
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lung Diseases, Emphysema
Alpha1-antitrypsin Deficiency Registry
To collect data from the 37 participating clinical centers on patients with alpha1-antitrypsin deficiency, including those who received replacement therapy with an intravenous preparation of alpha1-proteinase inhibitor (A1Pi)…
- Conditions
- Lung Diseases, Emphysema, Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT00005292
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease, COPD
The Effect of Breathing Helium-Hyperoxia During Pulmonary Rehabilitation in Patients With COPD
The purpose of this study is to examine whether breathing helium-hyperoxia during exercise in a pulmonary rehabilitation program can improve the exercise tolerance and health related quality of life of patients with Chronic…
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Lung Diseases
- Trial name
- NCT00406705
- Testing
- Helium-Hyperoxia
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- University of Alberta
Diabetes Mellitus, Type 1
A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II
Aralast NP (alpha-1 antitrypsin, AAT), an alpha-1 proteinase inhibitor (human), was the drug to be tested in this clinical trial.
- Trial name
- RETAIN (NCT01183455)
- Testing
- Aralast NP
- Where
- 15 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Emphysema, COPD
AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation
The purpose of this study is to characterize the safety and efficacy of the AeriSeal System in patients with advanced upper lobe predominant emphysema and significant collateral ventilation as determined by the Chartis System.
- Conditions
- Pulmonary Emphysema, COPD, Lung Diseases
- Trial name
- CV+ (NCT01460108)
- Testing
- AeriSeal System
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
Alpha 1-Antitrypsin Deficiency
EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin
European Alpha-1 Research Collaboration (EARCO) is a pan-European network committed to promoting clinical research and education in alpha-1 antitrypsin deficiency (AATD).
- Trial name
- EARCO (NCT04180319)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Alpha 1-Antitrypsin Deficiency
Alpha-1 Research Registry
The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers.
- Trial name
- NCT04157049
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Alpha-1 Foundation
Emphysema or COPD
Introduction of the Vapor Treatment in The Netherlands
Rationale: The bronchoscopic lung volume reduction treatment using vapor was found to be effective and the treatment has an acceptable safety profile.
- Trial name
- NEVEL (NCT04029077)
- Testing
- NA: intervention is not part of the study
- Sponsor
- University Medical Center Groningen
Emphysema
Zephyr Valve Registry (ZEVR)
The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.
- Trial name
- ZEVR (NCT04186546)
- Testing
- Zephyr Valve Procedure
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Pulmonx Corporation
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Chronic Obstructive Pulmonary Disease, COPD
Activity Monitor Use in COPD Patients Undergoing Rehabilitation
In patients with Chronic Obstructive Pulmonary Disease (COPD) lifestyles with lower physical activity levels have been shown to increase the risk of hospital admissions and shorten survival rates.
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis
- Trial name
- NCT02895152
- Testing
- Feedback
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Northern Care Alliance NHS Foundation Trust
Emphysema
REACH SVS Control Patient Cross-Over Study
This is a multicenter, prospective study designed to evaluate performance of the SVS in the REACH SVS control patients. The study is expected to enroll up to 20 patients at up to 12 sites with up to 6 patients per site.
- Trial name
- NCT02914340
- Testing
- Spiration Valve System
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Olympus Corporation of the Americas
Respiratory Distress Syndrome, Pneumothorax/Pulmonary Intersticial Emphysema
Very Early Surfactant and NCPAP for Premature Infants With RDS
The present study will test the use of very early nasal continuous airway pressure(NCPAP)with and without surfactant in premature infants with clinical evidence or respiratory distress syndrome.
- Conditions
- Respiratory Distress Syndrome, Pneumothorax/Pulmonary Intersticial Emphysema, Chronic Lung Disease
- Trial name
- CNRNCPAP (NCT00563641)
- Testing
- Very early surfactant and bubble NCPAP, bubble NCPAP
- Where
- Colombia
- Volunteers
- 278 people
- Sponsor
- Colombian Neonatal Research Network
alpha1 Anti-trypsin, Pre-Eclampsia
Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic Women
Intrauterine growth restriction (IUGR) is defined as a velocity of fetal growth less than the normal fetus growth potential for a specific neonate as per the race and gender.
- Conditions
- alpha1 Anti-trypsin, Pre-Eclampsia, Intrauterine Growth Restriction
- Trial name
- NCT05622838
- Testing
- Alpha1 -Antitrypsin level
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Assiut University
Advanced Upper Lobe Predominant Emphysema
Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema
The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in treating patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00716053
- Testing
- BLVR
- Volunteers
- 225 people
- Sponsor
- Aeris Therapeutics
Alpha 1-Antitrypsin Deficiency
Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency
OBJECTIVES: I. Establish cell lines from patients with alpha 1-antitrypsin deficiency in order to examine genetic traits that predispose to liver injury.
- Trial name
- NCT00005098
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- National Center for Research Resources (NCRR)
Heterogeneous Emphysema
Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures
This clinical trial evaluates the impact of catheter-based measurement of interloabr collateral ventilation prior to endoscopic lung volume reduction in patients with hetereogeneous emphysema and complete interlobar fissures in…
- Trial name
- NCT01902732
- Testing
- Implantation of valves (IBV)
- Where
- 5 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Biliary Atresia, Alagille Syndrome
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Noninvasive monitoring of liver fibrosis is an unmet need within the clinical management of pediatric chronic liver disease. While liver biopsy is often used in the initial diagnostic evaluation, subsequent biopsies are rarely…
- Conditions
- Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension
- Trial name
- FORCE (NCT02922751)
- Testing
- Liver Stiffness Measurement (LSM)
- Where
- 13 sites in United States, Canada
- Volunteers
- 552 people
- Sponsor
- Arbor Research Collaborative for Health
HIV Infections, AIDS
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
Background: The incidence of lung cancer is quite high among people with the human immunodeficiency (HIV) virus. Frequent smoking may explain that cancer increase, given that 50% to 70% of HIV-infected people are current smokers.
- Conditions
- HIV Infections, AIDS, Lung Cancer, Tobacco Addiction
- Trial name
- NCT00491335
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)